Tvardi Therapeutics
TVRD
146 hedge funds and large institutions have $563M invested in Tvardi Therapeutics in 2018 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 50 increasing their positions, 27 reducing their positions, and 17 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
96% more call options, than puts
Call options by funds: $20.7M | Put options by funds: $10.6M
94% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 17
85% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 27
56% more capital invested
Capital invested by funds: $360M → $563M (+$203M)
12% more funds holding
Funds holding: 130 → 146 (+16)
0.03% more ownership
Funds ownership: 1.63% → 1.66% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$39M |
| 2 |
BlackRock
New York
|
+$10.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.23M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.12M |
| 5 |
NC
Nexthera Capital
New York
|
+$6.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.58M |
| 2 |
JP Morgan Chase
New York
|
-$3.57M |
| 3 |
CG
Carmignac Gestion
Paris,
France
|
-$2.08M |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
-$2.06M |
| 5 |
CCMW
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
|
-$1.49M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MWNA
151
Marshall Wace North America
New York
| – | -$707K | -1,026 | Closed |
|
|
BFM
152
Boothbay Fund Management
New York
| – | -$421K | -611 | Closed |
|
|
MIM
153
MetLife Investment Management
Whippany,
New Jersey
| – | -$220K | -319 | Closed |
|
|
MLICM
154
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$166K | -241 | Closed |
|
|
EDRH
155
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$88K | -128 | Closed |
|
|
QT
156
Quantbot Technologies
New York
| – | -$74K | -108 | Closed |
|
|
AWA
157
Acorn Wealth Advisors
Grand Blanc,
Michigan
| – | -$17K | -24 | Closed |
|
|
RE
158
RBC Europe
London,
United Kingdom
| – | -$13.8K | -20 | Closed |
|
|
PIA
159
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$9K | -13 | Closed |
|
|
CF
160
Centaurus Financial
Anaheim,
California
| – | -$4K | -6 | Closed |
|
161
SEI Investments
Oaks,
Pennsylvania
| – | -$2K | -3 | Closed |
|
|
TRCT
162
Tower Research Capital (TRC)
New York
| – | -$1K | -1 | Closed |
|
TVRD Hedge Fund Activity: Q3 2018 in Review
146 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2018, worth a combined $563M — up 56% from $360M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new TVRD positions and 17 closed out — a net gain of 16 holders — while 50 added to existing stakes and 27 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $39M. The largest seller was Deutsche Bank, cutting an estimated $3.58M.
- 146 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2018, up from 130 in Q2 2018.
- Funds reported $563M of Tvardi Therapeutics stock for Q3 2018, up 56% quarter-over-quarter.
- 33 funds opened new Tvardi Therapeutics positions in Q3 2018 and 17 closed out, a net change of +16 holders.
- The largest Tvardi Therapeutics buyer in Q3 2018 was T. Rowe Price Associates, an estimated $39M added.
- The largest Tvardi Therapeutics seller in Q3 2018 was Deutsche Bank, an estimated $3.58M sold.
Based on aggregated 13F filings for Q3 2018.